Gene Therapy Casgevy denied for failing step therapy by Humana?

Humana's specific coverage criteria for gene therapy casgevy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Applies Step Therapy to Casgevy — and the Limits of That Approach

Step therapy (also called "fail-first") policies require patients to try and fail one or more lower-cost treatments before a plan will cover a higher-cost therapy. For Casgevy, Humana's step-therapy requirement likely means demonstrating an inadequate response to, or intolerance of, existing disease-modifying therapies. In many cases, patients being referred for gene therapy have already failed or are not candidates for these prior-line treatments — the documentation simply needs to make that explicit.

## Why This Denial Is Appealable

Federal and most state laws recognize step-therapy exemptions when prior-step therapies are contraindicated, were previously tried and failed, or would cause harm. Under ACA §2719 and ERISA §503, step-therapy denials are fully appealable. Many states have enacted step-therapy reform laws that require plans to grant exemptions when specific clinical conditions are met. Even without a state law, the external-review process allows an IRO to assess whether the step-therapy requirement is clinically appropriate in your specific case.

## Federal Appeal Framework

• Step-therapy exemption request: File simultaneously with or before the formal appeal. Humana must have a process for exempting patients from step-therapy when clinical criteria are met.
• Internal appeal: Submit with complete prior-treatment documentation. Timeline begins from the denial notice.
• External review: Available approximately four months from final internal denial. An IRO evaluates clinical appropriateness, not just administrative compliance.
• Expedited review: Available when waiting would seriously harm your health.

## Documentation to Gather

1. Prior treatment history — exhaustive: For every treatment Humana's step-therapy policy requires, document: the drug name, start date, end date, doses used (from chart records), the reason for discontinuation or inadequate response, and the treating physician's assessment. 2. Medical contraindication or ineligibility: If any required prior-step therapy is contraindicated or clinically inappropriate for you, obtain a letter from your hematologist documenting the specific clinical reason. 3. Disease progression records: Documentation showing that your disease has progressed or remained inadequately controlled despite prior therapy. 4. Prescriber letter: A letter from your hematologist explaining why proceeding directly to Casgevy is medically necessary and why continued step-therapy would be harmful or futile. 5. Applicable guideline reference: Reference from your hematologist to the relevant ASH or professional society guidelines regarding when gene therapy is appropriate — without quoting specific numbers.

## Criteria-Mapping Strategy

Obtain Humana's step-therapy criteria for Casgevy from the denial letter or Humana's published policy. List each required prior step. For each step: either (a) document that you completed it with the outcome, or (b) document the clinical reason it was not appropriate. Attach the FDA prescribing label's indicated population description to show that patients with your clinical profile are within the approved population regardless of step-therapy status. Step-therapy policies cannot override an FDA-approved indication when clinical circumstances justify the exemption.